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1. Introduction  
Tumor necrosis factor (TNF) is a proinflammatory cytokine involved in the pathogenesis of 
rheumatoid arthritis and other chronic inflammatory diseases. TNF also plays a critical role 
in host responses to intracellular pathogens and in granuloma formation and maintenance. 
The TNF-α inhibitors are a class of highly effective, targeted anti-inflammatory medications 
in widespread use for the treatment of rheumatoid arthritis. However, evidence has 
accumulated since the introduction of the TNF-antagonists that they are also associated with 
an increased risk of granulomatous infections, including tuberculosis and non-tuberculous 
mycobacterial (NTM) infections.  
This chapter will review the literature on the role of TNF in response to mycobacterial 
infection, the various TNF-α inhibitors and their biological differences, and the indications 
for TNF-α inhibitors in the treatment of rheumatoid arthritis. We will also review the 
literature to date on the risk of tuberculosis associated with rheumatoid arthritis and TNF-
antagonist therapy. We will discuss the clinical evaluation and treatment of latent 
tuberculosis infection in the setting of proposed TNF-antagonist therapy, as well as the 
presentation and treatment of active tuberculosis. We will review the current literature on 
the risk of NTM disease associated with TNF-α inhibitor therapy, as well as the 
presentation, treatment, and prevention of NTM disease in this setting.  
2. TNF and TNF-α inhibitors 
2.1 TNF biology 
TNF is produced primarily by activated monocytes/macrophages, T- and B-lymphocytes, 
and natural killer cells. It is made as a transmembrate protein (tmTNF), which is then 
cleaved to a soluble form (sTNF). Three monomers then associate to form trimeric TNF, 
which is biologically active. This trimeric TNF binds to cell-surface receptors TNFR1 and 
TNFR2. Both TNFR1 and TNFR2 can signal pro-inflammatory pathways and anti-apoptotic 
pathways. TNFR1 can also signal via death domain caspase-dependent pathways to induce 
apoptosis.  
TNF plays a major role in the initial host response to infection. With respect to tuberculosis, 
TNF is involved in macrophage activation; it increases the phagocytic capacity of the 
macrophage and enhances its killing of intracellular bacteria, via the generation of reactive 
nitrogen and oxygen species (Bekker et al. 2001). TNF also stimulates macrophages and T-
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lymphocytes to produce chemokines, and induces the expression of vascular adhesion 
molecules (Roach et al. 2002). These activities recruit immune cells and promote a focused 
accumulation of cells at the site of infection, which sequesters the mycobacteria and 
prevents their dissemination. This focused accumulation of cells is known as the granuloma, 
and TNF is involved in both the formation of the granuloma and the maintenance of its 
integrity. In TNF-deficient mice infected with M. tuberculosis, granuloma formation is 
delayed and malorganized. Treating chronically tuberculosis-infected mice (which are used 
as a model to simulate latent tuberculosis infection in humans) with a TNF-neutralizing 
antibody results in an increased bacillary load, compromised granuloma structure, and 
shortened survival (Mohan et al. 2001).   
TNF therefore plays a critical role in the host response to mycobacterial infection, via its role 
in macrophage activation, cell recruitment, granuloma formation, and maintenance.   
2.2 TNF-α inhibitors 
There are currently four anti-TNF monoclonal antibodies in clinical use for the treatment of 
rheumatoid arthritis; infliximab, adalimumab, golimumab, and certolizumab pegol. 
Infliximab is a chimeric monoclonal antibody containing a human immunoglobulin (Ig)G1 
constant region and a murine variable region. Adalimumab and golimumab both contain 
human IgG1 constant and variable regions. Certolizumab pegol is a pegylated, humanised 
monoclonal anti-TNF Fab’ (fragment, antigen binding) fragment. Infliximab is administered 
by intravenous infusion. Adalimumab, certotolizumab and golimumab are administered by 
subcutaneous injection, usually every other week.  
Etanercept is a soluble TNF receptor; the only one of its kind in clinical use. It is comprised 
of two extracellular domains of human TNFR2 fused to the Fc (fragment, crystallizable) 
fragment of human IgG1. It binds trimeric TNF and lymphotoxin. It is administered by 
subcutaneous injection, usually once or twice per week.  
All of the TNF-antagonists are approved for use in rheumatoid arthritis. They are also variably 
in use for the treatment of other chronic inflammatory conditions, including psoriatic arthritis, 
plaque psoriasis, ankylosing spondylitis, Crohn’s disease, and ulcerative colitis.  
There are several notable differences between the various TNF inhibitors. Firstly, peak blood 
levels of infliximab are several times greater than those of etanercept and adalimumab 
(Wallis 2008). The clinical implication of this difference is unclear, however, given that the 
infection risk with adalimumab seems similar to that of infliximab (see below). Also, the 
various TNF-antagonists may bind soluble TNF (sTNF) with different affinities, but results 
are conflicting; one study has shown that etanercept binds sTNF with less affinity than 
infliximab (Scallon et al. 2002), whereas another study has shown the opposite (Nesbitt et al. 
2006 as cited in Wallis 2008). Additionally, the anti-TNF monoclonal antibodies inhibit T-cell 
activation and cytokine expression (other than TNF), whereas etanercept has little or no 
effect in these systems (Saliu et al. 2006).  
The differential binding of the TNF antagonists for transmembrane TNF (tmTNF) may 
partially explain differences in clinical efficacy and possibly infection risk. Infliximab binds 
transmembrane TNF (tmTNF) with more affinity than etanercept, and inhibits tmTNF-
mediated cellular activation more effectively (Scallon et al. 2002). Additionally, some studies 
have shown that the anti-TNF antibodies can cross-link tmTNF and thereby induce 
apoptosis in TNF-expressing T cells, whereas etanercept lacks this activity (Wallis 2008). 
This induction of apoptosis may play a role in their efficacy in Crohn’s disease, where 
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defective apoptosis in gut lymphocytes is believed to be a major feature in the pathogenesis 
of the disease (Wallis 2008).  
However, the clinical importance of tmTNF-mediated apoptosis is still a matter of debate, as 
highlighted by the activity of certolizumab pegol. Certolizumab cannot crosslink tmTNF nor 
participate in complement activation given its monovalent structure and lack of Fc. It 
therefore cannot induce apoptosis in TNF-expressing cells. However, it appears to be 
effective in the treatment of Crohn’s disease (Sandborn et al. 2007), and does appear to 
increase the risk of tuberculosis (see below). This implies that the induction of cell death 
may be less important in the mechanism of action of these medications than other properties 
(Wallis 2008). Nonetheless, several animal experiments have shown that selective inhibition 
of sTNF (and not tmTNF) may be beneficial in reducing infection risks. For instance, one 
study showed that inhibition of both sTNF and tmTNF protected from clinical signs of 
inflammation in a murine model of rheumatoid arthritis, yet increased the risk of 
reactivation of latent tuberculosis, and increased susceptibility of infection to Listeria 
monocytogenes (Spohn et al. 2007). However, specific inhibition of sTNF, while sparing 
tmTNF was still effective in reducing inflammation, yet did not increase the risk of infection 
with these pathogens.  
2.3 TNF-α inhibitor therapy in rheumatoid arthritis  
The first randomized controlled clinical trial of a TNF antagonist was published in 1994; this 
study showed a significant improvement in signs and symptoms of rheumatoid arthritis 
compared with placebo (Elliott et al. 1994). There have since been numerous clinical trials 
demonstrating the efficacy of all five TNF antagonists in rheumatoid arthritis, in various 
endpoints including signs and symptoms, health-related quality of life, and delayed 
progression of joint damage (Saag et al. 2008). TNF-antagonists given alone are not 
significantly better than methotrexate in controlling rheumatoid arthritis signs and 
symptoms, but they do result in a significant improvement compared with traditional 
DMARDs when given together with methotrexate in patients who do not completely 
respond to DMARD therapy. Therefore, treatment with TNF- antagonists in combination 
with methotrexate or other DMARDs is recommended in most guidelines for rheumatoid 
arthritis patients who partially respond to at least one DMARD including methotrexate 
(Saag et al. 2008).  
The American College of Rheumatology also recommends the use of TNF antagonists in 
combination with methotrexate in DMARD-naive patients with early rheumatoid arthritis 
(disease duration of less than 3 months) who have high disease activity and markers of poor 
prognosis (Saag et al. 2008). However, the European League against Rheumatism 
recommends initial treatment with methotrexate alone in early rheumatoid arthritis because 
of a favourable benefit to risk ratio, given that better outcomes with early combination 
therapy are seen mainly in a subset of patients with severe disease (Combe et al. 2007). 
To date, there have not been any randomized clinical trials comparing the efficacy of the 
different TNF-α inhibitors.  
3. Tuberculosis in the setting of TNF-α inhibitors 
3.1 The risk of tuberculosis associated with rheumatoid arthritis 
Patients with autoimmune rheumatic diseases, including systemic lupus erythematosus and 
rheumatoid arthritis, are at higher risk of infections, including tuberculosis. This increased 
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risk is thought to be related to the immune disturbances caused by the disease itself, as well 
as to treatment with immunosuppressive drugs. Several studies have looked at the risk of 
tuberculosis associated with rheumatoid arthritis.   
In Quebec, Canada, one retrospective cohort study of 24,282 patients with rheumatoid arthritis 
identified 50 cases of tuberculosis from 1992 to 2003 (Brassard et al. 2009). The standardized 
incidence rate was 45.8 cases per 100,000 person-years of follow-up. This rate is much higher 
than the incidence of tuberculosis in the general population of Quebec, of 4.2 cases per 100,000 
person-years. This translates to a standardized incidence ratio of 10.9 (95% confidence interval 
[CI] 7.9–15.0). Using a nested-case control design, they found that some of the increased risk 
may be explained by the use of non-biologic DMARDs; the adjusted relative risk of 
tuberculosis was 2.4 (95%CI 1.1–5.4) with corticosteroid use and 3.0 (95%CI 1.6–5.8) with other 
nonbiologic DMARD use (including methotrexate, leflunamide, and others).  
These results are in stark contrast to an American study (Wolfe et al. 2004) which prospectively 
followed 10,782 patients with rheumatoid arthritis from 1998 to 1999 with surveys. They only 
identified one case of tuberculosis, translating to a rate of 6.2 cases per 100,000 patients. This 
rate is not increased compared with the rate in the general US population. However, this study 
may have underestimated the rate of tuberculosis in rheumatoid arthritis, owing to decreased 
study participation of foreign-born and minority populations.   
In Asia, one prospective Japanese study identified 4 cases of tuberculosis in 5544 patients 
with rheumatoid arthritis followed for 1 year (Yamada et al. 2006). The age-adjusted 
incidence of tuberculosis was 42.4 per 100,000 patients, and the relative risk for tuberculosis 
was 3.21 (95%CI 1.21-8.55) compared with the general Japanese population. They also found 
a much higher risk of tuberculosis in men compared with women. One retrospective Korean 
study of 1285 rheumatoid arthritis patients found 9 cases of tuberculosis from 2001 to 2005, 
resulting in a rate of 257 per 100,000 person-years of follow-up (Seong et al. 2007). This rate 
was 8.9 times higher than the rate in the general Korean population (95%CI 4.6–17.2).  
A report from Spain (Carmona et al. 2003) studied a cohort of 788 patients with rheumatoid 
arthritis over 10 years, and found 7 cases of tuberculosis, yielding a mean annual incidence 
(1990–2000) of 134 per 100,000 patients. The incidence risk ratio of pulmonary tuberculosis 
in patients with rheumatoid arthritis compared to the general Spanish population was 3.68 
(95%CI 2.36–5.92). A Swedish study examined a cohort of rheumatoid arthritis patients from 
1999 to 2001 and looked at the risk of hospitalization for tuberculosis (Askling et al. 2005). 
They found that rheumatoid arthritis patients were at a two-fold increased risk of being 
hospitalized for tuberculosis compared with the general population (relative risk 2.0, 95%CI 
1.2-3.4).  
In summary, several observational studies from different countries around the world have 
shown that patients with rheumatoid arthritis are at increased risk of tuberculosis. This 
increased risk is independent of TNF-α inhibitors, but may be due to other disease 
modifying drugs, and possibly to the disease itself. The magnitude of the relative risk ranges 
between 2 and 11. Only one study, which was from the United States, showed no increased 
risk of tuberculosis in rheumatoid arthritis patients compared with the general population.  
3.2 The risk of tuberculosis associated with TNF-α inhibitors 
Studies estimating the risk of tuberculosis associated with TNF-α inhibitors face many 
challenges. For one, tuberculosis rates are relatively low in North America and Europe, and 
they may vary significantly by country, ethnicity of the individual, and underlying medical 
condition. Also, patients with rheumatoid arthritis and other rheumatic diseases may be 
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treated with several different disease modifying medications, in addition to TNF-α inhibitors, 
which may also increase the risk of tuberculosis. Additionally, when studying the risk 
associated with a particular drug, it is unclear if the risk is increased only during active drug 
treatment, or if there is a carry-over effect  when the patient is no longer taking the medication 
but is still at risk. Also, the rate of active tuberculosis is affected by the rate of screening and 
treatment for latent tuberculosis infection, which may vary based on local practice.   
Despite these challenges, a large number of observational studies from all over the world 
have been conducted examining this issue. The methods of data collection have varied from 
retrospective voluntary reporting to prospective national registries. The results are also 
variably reported; some report rates of tuberculosis per number of people treated with drug, 
while others report rates per number of people treated per time, and time may be time on 
drug or time at risk or follow-up time. The major studies examining the risk of tuberculosis 
associated with TNF-α inhibitors will be reviewed below, and are summarized in Table 1. 
 
Study (first 
author, year) 
Country Type of study 
TB incidence rate per 100,000 
person-years 
Rate 
ratio 
I:A:E 
Rate ratio 
compared 
with  RA Infliximab Adalimumab Etanercept
FDA AERS 
(Wallis, 2004) 
USA 
Cases 
voluntarily 
reported 
54* -- 28* 
1.9:N/A:
1 
-- 
PharMetrics 
(Brassard, 
2006) 
USA 
Search of 
pharmacy 
database 
-- -- -- -- 1.5 
NDB 
(Wolfe, 2004) 
USA 
Data from 
registry 
52.5 -- 0 N/A 10∞ 
RATIO 
(Tubach, 2009) 
France 
Data from 
registry 
187.5 215.0 9.3 
20.1:23.1:
1 
-- 
RABBIT 
(Listing, 2005) 
Germany
Data from 
registry 
310 -- 0 N/A -- 
GEARSPR 
(Fonseca, 2006) 
Portugal
Data from 
registry 
1754* 2339* 300* 
5.8:7.8:1.
0 
-- 
BIOBADASER 
(Gomez-Reino 
2007) 
Spain 
Data from 
registry 
383 176 114 3.4:1.5:1 2.4 
BIOBADASER 
(Gomez-Reino 
2003) 
Spain 
Data from 
registry 
1503 -- 0 N/A 15.8 
ARTIS 
(Askling, 2005) 
Sweden
Data from 
registry 
145 -- 80 
1.8:N/A:
1 
4.0 
BSRBR (Dixon, 
2010) 
UK 
Data from 
registry 
123 217 53 2.2:4.2:1 -- 
Single centre 
cohort (Seong, 
2007) 
Korea 
Retrospective 
chart review 
2558 -- 0 N/A 30.1 
TB: tuberculosis; I:A:E: infliximab:adalimumab: etanercept relative risk; RA:rheumatoid arthritis, *:cases 
per 100,000 treated persons; --: not reported; N/A: not applicable; ∞: for inflixmab only 
Table 1. Major studies reporting tuberculosis risk in patients treated with TNF-α antagonists 
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Several studies have been published estimating the incidence of tuberculosis associated with 
TNF inhibitors in North America. In 2004, Wallis et al. reported rates of tuberculosis and 
other granulomatous infections associated with infliximab and etanercept (Wallis et al. 
2004). The cases were voluntarily reported to the United States Food and Drug 
Administration (FDA) Adverse Events Reporting System (AERS) from January 1998 to 
September 2002. A correction was published soon after (Wallis et al. 2004), which removed 
erroneously included tuberculosis cases from Europe. This study published a tuberculosis 
rate of 54 per 100,000 treated persons associated with infliximab, and 28 per 100,000 persons 
treated with etancercept. Infliximab was therefore associated with a two-fold increased risk 
compared with etanercept. Their overall tuberculosis rate was 41 per 100,000 persons. 
Wolfe et al. published a study in 2004 that looked at rates of tuberculosis in patients with 
rheumatoid arthritis registered in the National Data Bank (NDB) of Rheumatic Disease in 
the United States (Wolfe et al. 2004). They prospectively collected data on rheumatoid 
arthritis patients treated with infliximab and etanercept over a 30-month period, from 
January 2000 to June 2002. They identified 4 cases of tuberculosis, all in patients treated with 
infliximab; this translates to a rate of 62 per 100,000 infliximab-treated persons. 
Brassard et al. published a study in 2006 that used medical and pharmaceutical claims data 
to determine rates of tuberculosis in American patients with rheumatoid arthritis (Brassard 
et al. 2006). A nested case-control design was used to estimate the risk of tuberculosis 
associated with disease modifying anti-rheumatic drugs (DMARDs), including infliximab 
and etanercept. They identified 357 cases of tuberculosis, 51 of which were associated with 
anti-TNF agents. This translates to a tuberculosis rate of 257 per 100,000 person-years of 
follow-up associated with anti-TNF agents. The tuberculosis risk was higher with infliximab 
than with etanercept (adjusted rate ratio 1.6 vs 1.2). However, cases of latent tuberculosis 
infection may have been misclassified as active disease (Mines & Novelli 2007). Indeed, the 
tuberculosis rate in the entire rheumatoid arthritis cohort was much higher than expected.  
The incidence of tuberculosis in the United States in the general population in 1999 was 6.4 
per 100,000 persons. The incidence in rheumatoid arthritis patients during the same year 
was 6.2 per 100,000 persons (Wolfe et al. 2004). The rates reported in these studies are 
therefore many times higher than these background rates (see Table 1). 
National registries of biological agents have been established in many European countries to 
collect data on the long-term effects of these medications. Studies using these registries have 
consistently shown increased risks of tuberculosis associated with TNF-α inhibitors. The 
first was from the BIOBADASER (Spanish Registry of Adverse Events of Biological 
Therapies in Rheumatic Diseases) registry (Gomez-Reino et al. 2003). This study published 
mostly prospectively collected data on rates of tuberculosis in patients with rheumatic 
diseases being treated with infliximab or etanercept in Spain from 1999 to 2002. They 
reported 17 cases of tuberculosis in patients receiving infliximab, 15 of whom had 
rheumatoid arthritis. There were no cases of tuberculosis in patients treated with etanercept. 
The tuberculosis incidence in patients receiving infliximab was 1,893 per 100,000 patients in 
2000 and 1,113 cases per 100,000 patients in 2001. The risk ratio of tuberculosis in patients 
treated with infliximab compared to the background rate in Spain was 90.1 (95%CI 58.8-
146.0) in 2000 and 53.0 (95%CI 34.5-89.0) in 2001. The risk ratio of tuberculosis in infliximab-
treated rheumatoid arthritis patients vs. rheumatoid arthritis patients not exposed to 
therapy was 19.9 (95%CI 16.2-24.8) in 2000 and 11.7 (95%CI 9.5-14.6) in 2001.  
A follow-up study using the same registry was published in 2007 (Gomez-Reino et al. 2007). 
This study prospectively collected data on patients in Spain treated with infliximab, 
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etanercept, and adalimumab from March 2002 (after national guidelines on screening and 
treatment of latent tuberculosis infection were introduced) to January 2006. They had 15 cases 
of tuberculosis translating to an incidence of 172 per 100,000 patient-years. The risk ratio 
compared with the general population was 7 (95%CI 3-13), and the risk ratio compared to 
Spanish rheumatoid arthritis patients was 2.4, which was not statistically significantly 
increased. There appeared to be differential risks posed by the three TNF-α inhibitors, with the 
risk seemingly highest with infliximab, but the differences were not statistically significant.   
A prospective French study using the RATIO (French Research Axed on Tolerance of 
Biotherapies) registry identified 69 cases of tuberculosis from 2004 to 2006 in patients treated 
with infliximab, etanercept, or adalimumab (Tubach et al. 2009). The tuberculosis incidence 
rate was 117 per 100,000 person-years (adjusted for sex and age), which is 12.2 times greater 
than the incidence of tuberculosis in the general French population. Most of this risk seemed 
to be caused by infliximab (standardized incidence ratio (SIR) = 18.6, 95%CI 13.4-25.8) and 
adalimumb (SIR = 29.3, 95%CI 20.3-42.4), rather than etanercept (SIR=1.8, 95%CI 0.7-4.3).  A 
Portugese registry, GEARSPR (Grupo de Estudos de Artrite Reumato´ ide da Sociedade 
Portuguesa de Reumatologia), also found that the risk of tuberculosis posed by infliximab 
and adalimumab was much higher than that posed by etanercept (Fonseca et al. 2006). They 
reported 13 cases of tuberculosis between 1999 to 2005 in patients exposed to anti-TNF 
therapy. The risk of tuberculosis with adalimumab and infliximab was 8-fold and 6-fold 
higher, respectively, than that with etanercept.  
Recently, a prospective observational study from the United Kingdom using the BSRBR 
registry (The British Society for Rheumatology Biologics Register) identified 40 cases of 
tuberculosis in patients on TNF-α inhibitors from 2001 to 2008 (Dixon et al. 2010). This 
resulted in a tuberculosis rate of 118 per 100,000 person-years at risk, which is 8 times higher 
than the general UK population. Again, the risk of tuberculosis was greater with the 
monoclonal antibiodies than the soluble TNF receptor. Specificially, the rate of tuberculosis 
associated with adalimumab was 144 per 100,000 person-years on therapy, that with 
infliximab was 136 per 100,000 person-years, and the rate with etancercept was 39 per 
100,000 person-years. The adjusted incidence rate ratio compared with etancercept was 3.1 
for infliximab and 4.2 for adalimumab.   
Smaller registries from Sweden and Germany have also reported an increased risk of 
tuberculosis in association with TNF-α inhibitors. The Swedish registry ARTIS (Anti-
Rheumatic Treatment in Sweden) identified 15 cases of tuberculosis, with an incidence of 
118 per 100,000 person-years treated (Askling et al. 2005). Rheumatoid arthritis patients 
treated with TNF antagonists had a 4-fold increased risk of tuberculosis compared with 
rheumatoid arthritis patients not treated with TNF antagonists. The risk was 2-fold higher 
with infliximab versus etanercept. The German registry RABBIT (Rheumatoid Arthritis- 
Observation of Biologic Therapy) identified 1 case of tuberculosis in a patient on infliximab; 
there were no cases in patients on etanercept (Listing et al. 2005).    
An important Asian study describing rates of tuberculosis amongst patients on TNF-α 
inhibitors comes from Korea (Seong et al. 2007). This publication reports retrospective data 
collected at one medical centre in Seoul between 2001 and 2005. They reviewed the records 
of 90 patients treated with infliximab and 103 patients treated with etancercept; they 
identified 2 cases of tuberculosis amongst infliximab-treated patients, and none with 
etanercept. The rate of tuberculosis with infliximab was 2558 per 100,000 person-years of 
follow-up, this was 30.1-fold higher than the risk of tuberculosis in the general Korean 
population, and was also higher than the risk of tuberculosis in Korean patients with 
rheumatoid arthritis.  
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In summary, this large body of epidemiological evidence confirms an increased risk of 
tuberculosis associated with TNF-α inhibitors, above national background rates and above 
rates in patients with rheumatoid arthritis. The risk of tuberculosis associated with TNF-
inhibitors appears to be between 1.5 and 30 times greater than the risk associated with 
rheumatoid arthritis alone.  Unfortunately, limitations of the available data make more 
precise estimates of risk impossible. 
The risk of tuberculosis differs amongst the various TNF-α inhibitors. The monoclonal 
antibodies infliximab and adalimumab portend more risk than the soluble TNF receptor 
etanercept (see Table 1 for relative risk estimates). Additionally, the time from initiation of 
treatment to onset of tuberculosis seems to be shorter with infliximab than etanercept. The 
FDA AERS study showed that median time from initiation of TNF-anatgonist therapy to 
presentation of tuberculosis was 17 weeks for infliximab versus 48 weeks for etanercept 
(Wallis et al. 2004); the Pharmetics study reported 17 weeks for infliximab and 79 weeks for 
etanercept (Brassard et al. 2006). The BSRBR reported a median time to tuberculosis 
diagnosis from the start of anti-TNF therapy of 13.4 months for etanercept, 5.5 months for 
infliximab, and 18.5 months for adalimumab (Dixon et al. 2010). Their results are somewhat 
surprising given the longer median onset time with adalimumab, which would be expected 
to behave similarly to infliximab. However, the RATIO study showed similar tuberculosis 
onset times for infliximab and adalimumab, with the onset time being longer with 
etanercept (Tubach et al. 2009). The reason for the difference in risk and time to 
development of tuberculosis amongst the drugs of this class is not known, but may be 
related to different pharmacokinetic properties of the drugs, differential binding of soluble 
and transmembrance receptors, and differential effects on immune cell function and death, 
as described in section 2.2.  
There has been little published to date on the risk of tuberculosis associated with the newer 
drugs certolizumab pegol and golimumab. However, two phase III placebo-controlled trials 
of certolizumab in patients with rheumatoid arthritis (RAPID 1 and 2) each reported 5 cases 
of active tuberculosis in the certolizumab arms, and none in the placebo arms (Keystone et 
al. 2008; Smolen et al. 2009), suggesting an increased risk.  
3.3 Diagnostic testing for latent tuberculosis infection 
In areas of low tuberculosis prevalence and transmission, most active tuberculosis cases 
associated with TNF-antagonists are thought to be related to progression of latent infection 
acquired in higher prevalence regions or time periods. It is therefore felt that the most 
effective way of preventing active tuberculosis is to identify and treat latent tuberculosis 
infections before the initiation of anti-TNF-α therapy. National guidelines or statements 
have been published by several countries providing recommendations in this regard; the 
major English language guidelines are summarized in Table 2. These statements provide 
significantly different recommendations in a number of areas. Recently, a European 
consensus statement has been published by the TBNET group on this matter, which 
provides its own recommendations (Solovic et al. 2010). 
The traditional method used to identify latent tuberculosis infection is the tuberculin skin 
test. This test elicits a cell-mediated, delayed hypersensitivity reaction after the volar aspect 
of the forearm is intradermally injected with purified protein derivative (PPD), a sterile 
extract derived from M. tuberculosis. The site of injection is observed within 48 to 72 hours; 
the largest diameter of the induration transverse to the long axis of the arm is recorded in 
millimetres. The test is positive if the induration is above a pre-specified size; the size cutoff 
for positivity varies depending upon the positive predictive value of the test.  
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Country 
(reference) 
TST 
TST: 
One or 
two step
Positive TST IGRA
Criteria for LTBI 
treatment 
LTBI 
treatment* 
USA (Centers for 
Disease et al. 
2004) 
All One 5 mm if IS, 10 
mm if increased 
risk, 15 mm if 
low risk 
No TST+, TST- if clinical 
or epidemiological 
risks 
9H 
France (Salmon 
et al. 2002) 
All One 10 mm No TST+, previous TB 
inadequately 
treated, CXR lesions 
>1 cm3 not treated 
2RZ or 3RH or 
9H 
Germany (Diel et 
al. 2009)† 
Only in certain 
circumstances¶ 
One 5 mm Yes IGRA+, abnormal 
CXR consistent with 
TB inadequately 
treated, history of 
exposure not treated 
9H or 4R 
Ireland 
(Kavanagh et al. 
2008) 
All One 5 mm if IS, 
others 10 mm 
No TST+ 9H or 4R or 
4RH 
Portugal 
(Fonseca et al. 
2006)† 
All Two 5 mm No TST+, consider in 
TST- 
9H 
Spain (Carmona 
et al. 2005) 
All Two 5 mm No TST+, previous TB 
inadequately 
treated, abnormal 
CXR consistent with 
TB inadequately 
treated 
9H 
Switzerland 
(Beglinger et al. 
2007) 
No N/A N/A Yes IGRA+, abnormal 
CXR consistent with 
past TB 
inadequately 
treated, history of 
exposure not treated 
9H or 4R 
UK (British 
Thoracic Society 
Standards of 
Care 2005) 
All One 5 mm if no 
BCG, 15 mm if 
BCG 
No TST+, previous TB 
or abnormal CXR 
inadequately 
treated, IS patients 
with epidemiologic 
risk 
6H or 3RH 
TBNET (Solovic 
et al. 2010) 
Only if no history 
of BCG  
One 10 mm Yes TST+ or IGRA+ 9-12H or 3RH 
TST: tuberculin skin test; IGRA: interferon gamma release assay; LTBI: latent tuberculosis infection; IS: 
immunosuppressed; mm: millimetres; BCG: Bacille Calmette-Guérin vaccination; H: isoniazid; R: 
rifampin; Z: pyrazinamide; ¶: TST should be given only if a discrepancy exists between strong 
epidemiological evidence of prior TB exposure and negative IGRA; *: the number is the number of 
months of latent TB treatment; †: English abstract only.  
The LTBI treatment regimen of rifampin and pyrazinamide for 2 months, presented in the French 
recommendations of 2002, is generally not a recommended regimen because of high rates of severe 
hepatotoxicity (Centers for Disease et al. 2001). 
Table 2. Published recommendations on identification and treatment of latent tuberculosis 
infection in the setting of TNF-α inhibitor therapy (Modified from Solovic et al. 2010) 
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Tuberculin skin testing does not distinguish between persistent M. tuberculosis infection and 
immunological memory of a previous infection that has been eradicated. Additionally, 
tuberculin skin test responses may be falsely positive in individuals who have been 
previously vaccinated with Bacille Calmette-Guerin (BCG) or who have nontuberculous 
mycobacterial infections, as the PPD contains antigens that are shared amongst many 
mycobacterial species. However, the BCG vaccine is less likely to be the cause of a positive 
test in adulthood if it is administered before 1 year of age (Menzies & Vissandjee 1992).  
Tuberculin skin test responses are decreased in rheumatoid arthritis (Ponce de Leon et al. 
2005), likely due to the use of immunosuppressive medications, but also possibly secondary 
to the disease itself. For this reason, some experts recommend reducing the size threshold 
for positivity in these patients (for example, to 5 mm) and/or repeated testing (boosting) 7-
10 days after a negative test (the two step skin test). These strategies may increase the 
sensitivity of the test, but reduce the specificity.  
More recently, tests that measure the cell-mediated reaction to M. tuberculosis antigens in 
vitro have been developed and  implemented in clinical practice. With these tests, peripheral 
blood cells are stimulated with specific M. tuberculosis antigens; T-cells previously sensitized 
to M. tuberculosis antigens then recognize them upon re-exposure and secrete a variety of 
cytokines, including interferon gamma. The tests measure release of interferon gamma, and 
are therefore termed interferon gamma release assays (IGRAs). One type of IGRA incubates 
peripheral blood mononuclear cells with M. tuberculosis antigens and measures the 
percentage of T-cells releasing interferon gamma via an enzyme-linked immunospot 
(ELISPOT) assay; this is commercially available as the T-SPOT.TB (Oxford Immunotec). In 
the other available test, whole blood is incubated with M.tuberculosis antigens and the 
amount of inteferon gamma released into the supernatant is measured using an enzyme-
linked immunosorbent assay (ELISA); this is the Quantiferon-TB Gold In-Tube (Cellestis). 
The major advantage of IGRAs over tuberculin skin tests is an increased specificity. This 
feature is derived from the fact that the stimulating antigens used in IGRAs are not found in 
Bacille Calmette-Guérin (BCG) vaccine nor in most non-tuberculous mycobacterial species. 
Therefore, IGRAs are less likely to produce a false-positive test in individuals with previous 
BCG vaccination or NTM infection (Pai et al. 2008). 
A question of particular relevance in the population of patients with rheumatic diseases is 
whether interferon gamma release assays have increased sensitivity compared with the 
tuberculin skin test, as patients with rheumatic diseases are known to have a reduced 
response to the tuberculin skin test. Calculating the sensitivy (and specificity) of IGRAs is 
challenging, because of the lack of a ‚gold standard‘ for the diagnosis of latent tuberculosis 
infection. Nonetheless, a number of such studies have been performed, as has a meta-
analysis (Pai et al. 2008). The results are inconsistent. The sensitivity seems to depend on the 
individual‘s level of immunosuppression and the IGRA test used, as the ELISPOT-based 
assay has been shown to be more sensitive in immunocompromised patients than the 
ELISA-based test (Pai et al. 2008; Solovic et al. 2010).  
A number of observational studies have been conducted to evaluate the clinical use of 
IGRAs as an alternative to the tuberculin skin test in identifying latent tuberculosis infection 
in patients with chronic inflammatory conditions. These studies have been compiled and 
reviewed by the TBNET group (Solovic et al. 2010). To summarize, they found that the 
results of IGRAs and tuberculin skin tests correlate poorly. However, correlation is best in 
areas with low tuberculosis prevalence and low rates of individuals with previous BCG 
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vaccination. IGRAs are more frequently positive than tuberculin skin tests in unvaccinated 
populations, suggesting that IGRAs are more sensitive than tuberculin skin tests in patients 
with chronic inflammatory conditions. Addtionally, positive IGRAs seem to be more closely 
associated with risk factors for latent tuberculosis infection, implying that they are more 
specific than the tuberculin skin test in this setting (Solovic et al. 2010).  
Despite this emerging evidence supporting the clinical utility of IGRAs, to date no studies 
have been conducted examining the positive predictive value of IGRA responses for the 
developent of tuberculosis in patients treated with TNF-α inhibitors. Additionally, some 
studies have shown discordant results between tuberculin skin tests and IGRAs, which are 
as yet unexplained. Concern regarding the increased cost of IGRAs above that of the 
tuberculin skin test has also hindered their universal acceptance.     
Most national guidelines, other than those from Germany and Switzerland,  currently 
recommend the tuberculin skin test as the diagnostic tool of choice for latent tuberculosis 
infection prior to TNF-α inhibitor therapy. The European TBNET consensus guidelines 
endorse the IGRA, but suggest the tuberculin skin test as an alternative in patients not 
previously BCG-vaccinated. Guidelines also vary in how the tuberculin skin test should be 
administered; some suggest a one-step skin test while others suggest boosting. The TBNET 
consensus guidelines do not recommend the two-step approach, because of limited evidence 
of increased sensitivity but considerable evidence of reduced specificity. Controversy also 
exists in the interpretation of the tuberculin skin test in this setting. Some guidelines suggest 
a reduced cut-off of 5 mm in order to increase sensitivity, while others suggest 10 or 15 mm.   
3.4 Clinical evaluation and treatment of latent tuberculosis infection 
Given the strong epidemiological evidence confirming an increased risk of reactivation of 
tuberculosis in patients receiving TNF-α inhibitors, all patients should be screened for latent 
tuberculosis infection prior to the initiation of TNF-antagonists; active tuberculosis infection 
should also be ruled out. The clinical evaluation should include the following: a history to 
assess for previous active tuberculosis, previous tuberculosis therapy, known exposure to 
active tuberculosis, a history of residing in a high prevalence area, and symptoms of active 
tuberculosis; a chest radiograph, to assess for features of previous or current active 
tuberculosis; and either a tuberculin skin test or IGRA. Any patient suspected of having 
active tuberculosis based on symptoms and/or chest radiographic abnormalities such as 
infiltrates, cavities, pleural effusion, or mediastinal lymphadenopathy should be thoroughly 
investigated to rule out active disease prior to initiation of anti-TNF-α therapy. This work-
up should include sputum microscopy for acid-fast bacilli and culture and/or aspiration or 
biopsy of extrapulmonary sites. Patients with confirmed active tuberculosis should be 
promptly treated based upon local guidelines and the patient’s M. tuberculosis drug 
susceptibility results. Initiation of TNF-α inhibitor therapy should be delayed; most would 
recommend initiation of TNF-antagonist therapy only after a full course of treatment has 
been completed.  
If there is no suspicion of active tuberculosis infection, the clinician must decide if the 
patient has a latent tuberculosis infection and requires prophylactic chemotherapy. The 
decision to treat a patient for latent tuberculosis infection should be based upon the entire 
clinical evaluation; local guidelines should be used to assist in defining those patients who 
require preventive chemotherapy (table 2) prior to the initiation of TNF-α  inhibitor therapy. 
Although etancercept has been shown to carry a much lower risk of causing progression of 
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latent tuberculosis infection to active disease than the monoclonal antibodies, current 
guidelines universally recommend tuberculosis prophylaxis prior to all TNF-α inhibitors.  
There has only been one study conducted which examined the effectiveness of preventive 
chemotherapy for latent tuberculosis infection prior to the initiation of TNF-antagonists 
(Carmona et al. 2005). This observational study came from Spain, where national 
recommendations were released in early 2002 that suggested patients be screened for latent 
tuberculosis infection with a chest x-ray and two-step tuberculin skin test using a 5 mm 
threshold, before the initiation of TNF-antagonist therapy. Patients diagnosed with latent 
tuberculosis infection were to receive 9 months of isoniazid therapy, and at least 1 month 
was to have been completed before starting a TNF-α inhibitor (infliximab, etanercept, or 
adalimumab). Tuberculosis rates in their biologics registry prior to the release of the 
recommendations were compared with those afterwards. They found a 78% reduction 
(incidence risk ratio 0.22, 95%CI 0.03-0.88) in rates of active tuberculosis after 
implementation of the recommendations. Additionally, there were no cases of serious liver 
toxicity amongst the 324 patients on isoniazid therapy for latent tuberculosis infection.  
Based on this study and several large studies published decades ago (Comstock et al. 1979; 
Anonymous 1982), many national guidelines recommend isoniazid therapy for a duration of 
9 months for the treatment of latent tuberculosis infection, both in general and prior to TNF-
antagonist therapy. However, some national guidelines recommend other validated but less 
effective regimens, including 6 months of isoniazid, 3-4 months of rifampicin plus isoniazid, 
and 4 months of rifampicin. The French guidelines are unique in recommending 4 months of 
rifampicin plus pyrazinamide as a potential regimen; this combination has been avoided by 
others because of a risk of severe hepatotoxicity (Centers for Disease et al. 2001).  
The duration of therapy required before starting anti-TNF-α therapy is also not well 
established, and national guidelines also vary in this regard. Most guidelines suggest a 1 
month delay, but some suggest that no delay is necessary, while others suggest completion 
of prophylaxis before starting TNF-antagonists.    
3.5 The presentation and treatment of active tuberculosis 
In areas of low tuberculosis prevalence, active tuberculosis most commonly develops due to 
reactivation of latent infection. However, there may also be an increased risk of primary 
progression to active disease of newly acquired tuberculosis in patients on TNF-α inhibitors 
who have high-risk exposures. Several cases of this have been described (Arend et al. 2007; 
Wallis et al. 2009) .  
The presentation of active tuberculosis in patients on TNF-α inhibitors appears to differ 
from classically described tuberculosis. When associated with TNF-α inhibitors, tuberculosis 
is more likely to be extra-pulmonary and more likely to be disseminated at presentation. 
One report looked at the patterns of disease in 70 cases of infliximab-associated tuberculosis. 
They found that 56% had extrapulmonary tuberculosis, and 24% had disseminated disease 
(Keane et al. 2001). In contrast, in cases of tuberculosis not associated with HIV infection, 
about 18% are extrapulmonary and less than 2% are disseminated (Rieder et al. 1990). 
Another series described the clinical characteristics of 130 infliximab-associated tuberculosis 
cases reported to the U.S. Food and Drug Administration, and found that 45% had 
extrapulmonary tuberculosis and 23% had disseminated disease (Raval et al. 2007). 
When tuberculosis is diagnosed, prompt treatment should be initiated. Treatment regimens 
should be based upon local guidelines and the patient’s M. tuberculosis drug susceptibility 
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results. Most recommend that TNF-α inhibitor therapy be discontinued, at least temporarily. 
However, discontinuation of anti-TNF therapy may be associated with a paradoxical 
worsening of tuberculosis disease. This  is felt to be similar to the immune reconstitution 
syndrome seen in HIV-infected persons who are treated with anti-retroviral therapy. When 
occuring in the setting of TNF-inhibitor withdrawal, the paradoxical reaction is believed to 
be due to recovery of TNF-dependent inflammation. The largest series describing such cases 
retrospectively reviewed charts of patients who developed infliximab-associated 
tuberculosis from 1999 to 2003 in three Spanish medical centres. They found six cases of 
tuberculosis, four (67%) of which were associated with a paradoxical reaction (Garcia Vidal 
et al. 2005). Others have described this paradoxical reaction in association with infliximab 
withdrawal (Belknap et al. 2005; Arend et al. 2007), etanercept withdrawal (Winthrop et al. 
2008), and adalimumab withdrawal (Wallis et al. 2009).  
The optimal treatment of the paradoxial reaction is currently unknown. Some recommend 
corticosteroid therapy (Garcia-Vidal et al. 2009) given favorable results in HIV-infected 
patients. Other case reports have described the successful re-institution of TNF-antagonist 
therapy to treat severe tuberculosis paradoxical reactions (Blackmore et al. 2008; Wallis et al. 
2009).  
Despite these case reports of paradoxical reactions associated with withdrawal of anti-TNF 
therapy, most experts believe that this phenomenon is relatively uncommon, and that 
discontinuation of TNF-α inhibitors upon diagnosis of active tuberculosis is advisable. The 
optimal timing of re-institution of TNF-α inhibitors is unknown, but many experts suggest 
completing a full course of anti-tuberculosis treatment before re-starting TNF-inhibitors 
(Solovic et al. 2010).  
4. Nontuberculous mycobacterial infections in the setting of TNF-α inhibitors 
Nontuberculous mycobacteria (NTM) include species of mycobacteria other than those 
belonging to the Mycobacterium tuberculosis complex and M. leprae. They are a large group of 
ubiquitous environmental organisms that can cause pulmonary and extrapulmonary 
infections. Pulmonary NTM disease is often associated with underlying structural lung 
disease, including chronic obstructive pulmonary disease and bronchiectasis. In many other 
cases, there is no obvious underlying lung disease or overt immune incompetence. The 
relative proportions of NTM lung disease patients with and without underlying lung 
disease probably varies by population, but it appears that the majority of cases occur 
without demonstrable predisposing factors. NTM organisms may be isolated from the 
sputum in the absence of clinically relevant disease, and thus the diagnosis of pulmonary 
NTM disease rests on the presence of multiple positive cultures, and clinical (symptoms and 
radiology) data (Griffith et al. 2007). Extrapulmonary NTM disease is less common than 
lung disease, and may manifest as a localized infection of  lymph nodes, skin, soft tissue, or 
bone, or may be disseminated. It is diagnosed when biopsy specimens of the involved 
organ(s) culture the causative organism, or, in the case of disseminated disease, with 
positive blood cultures (Griffith et al. 2007). 
4.1 The risk of NTM disease associated with TNF-α inhibitors  
Given the known role of tumor necrosis factor (TNF) in granuloma formation and 
maintenance, it is likely that TNF-α  inhibitors increase the risk of all granulomatous 
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infections, including NTM infection. However, in comparion to tuberculosis, relatively little 
has been published on this association. NTM infection is more difficult to study than 
tuberculosis, since the diagnosis is more complex as it relies on clinical data in addition to 
positive cultures. Additionally, in many jurisdictions, NTM isolation and NTM disease are 
not reportable to public health authorities. 
Most literature associating NTM disease with TNF-α inhibitors has been in the form of case 
reports; a broad range of different NTM species infecting different body sites have been 
described in association with infliximab, adalimumab, and etanercept therapy (van Ingen et 
al. 2008). However, incidence studies are scarce. In 2004, Wallis et al. reported rates of 
granulomatous infections in persons treated with infliximab and etanercept. The cases were 
voluntarily reported to the United States Food and Drug Administration (FDA) Adverse 
Events Reporting System (AERS) from January 1998 to September 2002. A correction was 
published soon after (Wallis et al. 2004), which removed erroneously included cases from 
Europe. This study identified 29 cases of unspecified NTM infections, which translates to a 
rate of 17 per 100,000 treated persons (Wallis et al. 2004). This is much higher than the 
background incidence of 4 cases per 100,000 persons, reported in the United States in 1996 
(Centers for Disease et al. 1996).  
An updated study of the same Medwatch database, extending the time period to 2007, 
reported 105 confirmed or probable cases of NTM infection associated with TNF-α 
inhibitors (Winthrop et al. 2009). These cases were most frequently associated with 
infliximab (n = 73, 69%), followed by etanercept (n = 25, 24%), and then adalimumab (n = 7, 
7%). Unfortunately, they did not have information regarding drug exposure, and so were 
unable to calculate rates of infection.   
Interestingly, the original report of the US FDA Medwatch data found that the incidence of 
NTM infection was significantly lower than the incidence of tuberculosis in patients on 
TNF-α inhibitors (Wallis et al. 2004). However, a more recent report, based on a survey of 
infectious disease physicians in the United States, found the opposite; there were more cases 
of NTM infection than tuberculosis infection associated with TNF-α inhibitors in the United 
States (32 vs. 17 cases) (Winthrop et al. 2008). This finding is not unexpected, given the low 
prevalence of tuberculosis in the United States, and the widespread belief that rates of NTM 
disease are increasing (Griffith et al. 2007), but it highlights the fact that NTM disease is an 
underrecognized but important complication of TNF-antagonist therapy.  
4.2 The presentation, treatment, and prevention of NTM disease associated with TNF-
α inhibitors  
Similar to tuberculosis, in the setting of TNF-α inhibitor therapy, extra-pulmonary and 
disseminated NTM disease appear to be more common. In the 2009 report of the US FDA 
Medwatch data, 56% of the confirmed or probable NTM cases were pulmonary, and 44% 
were extrapulmonary; 26% involved skin or soft tissue, 9% bone or joint, and 8% were 
disseminated (Winthrop et al. 2009). In contrast, in the United States during the period from 
1993 through 1996, the NTM isolates reported by state public health laboratories were 
divided as follows; 75% were pulmonary, 5% were from blood, 2% from skin/soft tissue, 
and 0.4% from lymph node isolates (Centers for Disease et al. 1996).  
Patients with rheumatoid arthritis, however, may be more likely than those with other 
indications for TNF-antagonist therapy to have pulmonary NTM disease. The US FDA 
Medwatch study showed that compared with patients with extrapulmonary NTM disease, 
patients with pulmonary NTM disease were 3.6 times more likely to have underlying 
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rheumatoid arthritis (95%CI 1.5–8.8) (Winthrop et al. 2009). There are several possible 
reasons for this. For one, rheumatoid lung disease, which can include bronchiolitis and 
bronchiectasis, occurs in about 10% of people with rheumatoid arthritis, and can predispose 
to NTM disease (Winthrop et al. 2009). Also, rheumatoid arthritis and NTM lung disease 
have similar epidemiologic risk profiles, as both occur more commonly in elderly women 
(Winthrop et al. 2009). Additionally, rheumatoid arthritis is more common in the elderly, 
who may have comorbidities predisposing to NTM lung disease, such as chronic obstructive 
pulmonary disease.  
NTM disease is associated with a high level of morbidity and mortality when it develops on 
TNF-α inhibitor therapy. In the report from Winthrop et al., 61% of patients with NTM 
infections were hospitalized, and 9% died (Winthrop et al. 2009).   
A broad range of different NTM species have been described in association with TNF-α 
inhibitors, including those of high and low pathogenicity (van Ingen et al. 2008). In the US 
Medwatch study, M. Avium was the most common etiologic organism reported (49%), 
followed by rapidly growing mycobacteria (19%), and M. marinum (8%) (Winthrop et al. 
2009). 
NTM disease seems to occur after many months of TNF-α inhibitor therapy. The report of 
the US FDA Medwatch data showed that the median time between TNF-α inhibitor start 
date and infection diagnosis was 43 weeks for infliximab (range 2-200 weeks), 35 weeks for 
etanercept (range 0-288 weeks), and 18 weeks for adalimumab (range 4–94 weeks) 
(Winthrop et al. 2009). This group therefore surmised that most cases represent newly 
acquired infection. However, given the natural course of pulmonary NTM disease, which 
typically is insidious in onset and slowly progressive, the possibility exists that some 
patients had undiagnosed pulmonary NTM disease before starting TNF-antagonist therapy.  
The experience of treating NTM disease in the setting of TNF-α inhibitor therapy is limited. 
Anti-TNF-α therapy should likely be held for an unknown duration. However, one case 
report described a paradoxical worsening of NTM disease after withdrawal of infliximab 
(Salvana et al. 2007), similar to the paradoxical reaction sometimes seen with tuberculosis; 
the clinician should be aware of this complication. Treatment of NTM disease is complicated 
because different regimens exist for the different NTM species. Futhermore, prolonged 
antimicrobial therapy is required and results are often disappointing; expert consultation 
should always be sought.  
The best approach to screening and prevention of NTM disease prior to initiation of TNF-α 
inhibitor therapy is unknown. Unlike tuberculosis, there is no evidence of a latent phase in 
NTM disease. Additionally, screening is complicated by the possibility of NTM colonization 
without active disease, and the ongoing environmental inoculation that is likely present. 
However, given the insidious nature of NTM disease and its slow progression, 
unrecognized NTM disease may be present in some patients prior to starting TNF-
antagonist therapy. Screening for such patients should be considered. Screening should 
include chest radiography, which must be done for all patients prior to starting TNF-α 
inhibitors to screen for tuberculosis. However, chest radiographs are not sensitive for 
detecting bronchiectasis or other parenchymal abnormalities associated with pulmonary 
NTM disease. Computerized tomography (CT) should therefore be considered in patients 
suspected of predisposing pulmonary diseases, including those with chronic unexplained 
cough. If chest CT is suggestive of possible NTM disease, sputum or bronchoscopy 
specimens should be cultured to rule out active NTM disease prior to initiation of TNF-
antagonist therapy (van Ingen et al. 2008; Winthrop et al. 2009). 
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During therapy with TNF-α inhibitors, patients should be regularly assessed to rule out 
active infections. With respect to NTM disease, repeated sputum cultures during therapy 
should be considered in the setting of chest symptoms or co-morbid pulmonary disease, as 
well as chest radiography or CT scans. Extrapulmonary disease should be thoroughly 
investigated, and biopsy specimens should be stained for acid-fast bacilli and cultured for 
mycobacteria (van Ingen et al. 2008). 
5. Conclusion 
The TNF-α inhibitors, including the four currently available anti-TNF monoclonal 
antibodies and the soluble TNF receptor, have revolutionized the treatment of rheumatoid 
arthritis and other chronic inflammatory diseases since their introduction over a decade ago. 
However, their use is associated with an increased risk of granulomatous infections, 
including tuberculosis and NTM disease. The biological basis of this infection risk is the 
critical role played by TNF in the host response to mycobacterial infection, via its role in 
macrophage activation, cell recruitment, and granuloma formation and maintenance.  
The magnitude of the risk of tuberculosis associated with TNF-antagonist therapy appears 
to be between 1.5 and 30 times above the risk associated with rheumatoid arthritis alone. 
The risk of tuberculosis differs amongst the various TNF-α inhibitors; the monoclonal 
antibodies portend more risk and are associated with a shorter tuberculosis onset time than 
the soluble TNF receptor. These differences may be related to different pharmacokinetic 
properties of the drugs, differential binding of soluble and transmembrance receptors, and 
differential effects on immune cell function and death.  
All patients should be clinically evaluated for latent tuberculosis infection prior to the 
initiation of TNF-α inhibitor therapy. This evaluation should include a history, chest 
radiograph, and either a tuberculin skin test or an IGRA. IGRAs appear to be more specific for 
latent tuberculosis infection than tuberculin skin tests; they may also be more sensitive but this 
has not been definitively established. Most national guidelines recommend the tuberculin skin 
test as the diagnostic tool of choice for latent tuberculosis infection in this setting. The 
treatment of latent tuberculosis infection prior to the initiation of TNF-α inhibitors has proven 
benefit. Isoniazid therapy for a duration of 9 months is the most commonly recommended 
regimen, although some national guidelines recommend other regimens. The duration of 
therapy required before starting anti-TNF-α therapy is not well established. 
The presentation of active tuberculosis in patients on TNF-α inhibitors is different from 
classically described tuberculosis;  it is more likely to be extra-pulmonary and more likely to 
be disseminated at presentation. Discontinuation of anti-TNF-α  therapy may be associated 
with a paradoxical worsening of tuberculosis disease, but discontinuation of therapy is still 
recommended in most guidelines.  
NTM disease is an under recognized but important complication of TNF-antagonist therapy. 
Some research has suggested that NTM disease may be more common than tuberculosis in 
the setting of TNF-α inhibitor therapy, however the magnitude of the risk of NTM disease in 
this setting is unknown. NTM disease is associated with a high level of morbidity and 
mortality when it develops on TNF-α inhibitor therapy and may have atypical 
presentations.  The best approach to screening and prevention of NTM disease prior to 
initiation of TNF-α inhibitor therapy is unknown. 
Future research should include prospective studies establishing the magnitude of the risk of 
NTM disease with TNF-α inhibitor therapy; such studies may guide development of 
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preventive strategies. Prospective studies estimating the positive predictive value of IGRA 
responses compared with tuberculin skin test responses for the developent of tuberculosis in 
patients treated with TNF-α inhibitors are also needed. Reports on treatment and outcomes of 
tuberculosis and NTM disease in the setting of TNF-α inhibitor therapy are also necessary.  
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